Future studies should focus on elucidating the precise molecular mechanisms by which PRMT1 contributes to MM pathogenesis, exploring its crosstalk with other signaling pathways, and assessing the efficacy of PRMT1 inhibitors in combination with existing therapeutic modalities. This evidence concerns the gene PRMT1 and Miyoshi myopathy.